MDWD: מקדם מחיר להכנסות MediWound Ltd.

The slow rollout of NexoBrid in the US and reliance on BARDA contracts are weighing on profits for MediWound Ltd. (MDWD). The shift in the P/S multiple clearly captures these fluctuations, where the value of 14.10 expresses the metric level. However, the drug's enzymatic ecosystem is revolutionizing burn treatment, while streamlined biopharmaceutical logistics with cold chain control ensure sustainable margins and a lack of product shortages.

Demand for innovative wound dressings in conflict zones directly impacts the revenue of MediWound Ltd. (MDWD), which is reflected in the company's smoothed P/S ratio. This multiple compares market capitalization to gross revenue, allowing investors to assess the premium paid for the business and determine the fairness of the asset's current valuation relative to its actual sales.